Immune cell therapy aimed at autoimmune diseases hits early snag

NCT ID NCT06548620

Terminated Disease control Sponsor: Nanjing Bioheng Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies. However, the study was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD19-targeted CAR-T cells
What this could lead to: If successful, this approach could offer a new way to control autoimmune diseases by resetting the immune system, potentially reducing reliance on lifelong medications.
What could go wrong: This trial was withdrawn before any patients enrolled, so no data exists. CAR-T therapy carries serious risks like cytokine release syndrome and infections, and its long-term safety in autoimmune diseases is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy anti-neutrophil cytoplasmic antibody-associated vasculitis granulomatosis with polyangiitis idiopathic inflammatory myopathy multiple sclerosis myasthenia gravis myeloid sarcoma neuromyelitis optica Sclerosis Sjogren syndrome synovial sarcoma systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANCA-ASSOCIATED VASCULITIS IIM MG MS NMO SPECTRUM DISORDER SCLEROSIS SLE SS

Contacts and locations

Locations

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 461499, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.